Trump’s chief of staff diagnosed with breast cancer

Susie Wiles, who recently made history as the first woman to serve as White House Chief of Staff, has been diagnosed with breast cancer at age 68. This development carries significant implications for European investors monitoring U.S. political stability and policy continuity—particularly those with exposure to American markets or dependent on consistent regulatory frameworks. Wiles has been instrumental in orchestrating Donald Trump's second presidency, wielding considerable influence over administrative priorities, staff management, and strategic direction. Her role as Chief of Staff places her at the epicenter of executive decision-making, overseeing policy implementation and ensuring alignment between the President's vision and federal agencies. Her institutional knowledge and operational effectiveness have been credited with establishing organizational discipline within an administration known for unpredictability. For European investors, leadership transitions in the U.S. Executive Office warrant close monitoring. The Chief of Staff position functions as a critical nodal point through which policy decisions flow—from trade agreements to regulatory reforms affecting European companies operating in American markets. Wiles' documented effectiveness in managing competing interests and implementing coherent policy strategy has provided a degree of predictability that investors value when assessing regulatory risk. The diagnosis raises questions about continuity in U.S. policy implementation at a crucial